Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Psych Stock to Unveil Breakthrough Pre-Clinical Research Findings

Stockhouse Editorial
1 Comment| November 2, 2021

{{labelSign}}  Favorites
{{errorMessage}}

Click to enlargeA public biotech company intends to release positive research findings and data next week.

Cybin Inc. (NEO: CYBN, NYSE American: CYBN, Forum) announced on Tuesday that it will host an in-person and virtual research and development briefing on the advancements to create a promising approach for patients in need of effective and safe prescription therapies in the mental health space on Monday, November 8, 2021 from 8:30 am to 9:30 am (EST).

Doug Drysdale, the company’s CEO said in a news release that people won’t want to miss this.

“We are on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. At a time when COVID has exacerbated the mental health crisis to epidemic proportions, the Cybin team has been exceptionally productive. We are excited to share the deeply meaningful scientific progress that we have made.”

He will join the company’s senior scientific research team on the briefing. The in-person session will take place at the Adrienne Arsht Center for the Performing Arts, within the Green Room, at the Wonderland Conference in Miami. The event will be followed by a Q&A session.

Click here to find out more about how to join the event.

Initially focused on psychedelic pharmaceutical therapies supporting research to advance psychedelic therapies centered on improving mental health and wellbeing, the Toronto-based life sciences company also made news last week after the launch of its EMBARK Psychedelic Facilitator Training Program.

The program offers psychedelic clinical trial facilitators the foundational training needed to provide skillful and ethical care to participants receiving psychedelic treatment. Led by a team of esteemed faculty, the training will kick off with an in-person training retreat at the Whidbey Institute, a home for transformational learning in Washington state. With an emphasis on experiential learning, the training includes an experiential training component, in addition to the core training and practice sessions on the EMBARK model.


FULL DISCLOSURE: Cybin Inc. is a client of Stockhouse Publishing.



{{labelSign}}  Favorites
{{errorMessage}}

Comments

No comments yet. Be first to comment!

Leave a Comment

You must be logged in to be able to post a comment.

Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today